Masuda, Norikazu http://orcid.org/0000-0002-7302-0278
Ohtani, Shoichiro
Takano, Toshimi
Inoue, Kenichi
Suzuki, Eiji
Nakamura, Rikiya
Bando, Hiroko
Ito, Yoshinori
Ishida, Kazushige
Yamanaka, Takashi
Kuroi, Katsumasa
Yasojima, Hiroyuki
Kasai, Hiroi
Takasuka, Tsuyoshi
Sakurai, Takaki
Kataoka, Tatsuki R.
Morita, Satoshi
Ohno, Shinji
Toi, Masakazu http://orcid.org/0000-0003-1488-9958
Clinical trials referenced in this document:
Documents that mention this clinical trial
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
https://doi.org/10.1007/s10549-020-05524-6
Funding for this research was provided by:
Japan Breast Cancer Research Group
Chugai Pharmaceutical Co., Ltd.
Article History
Received: 1 November 2019
Accepted: 8 January 2020
First Online: 17 January 2020
Compliance with ethical standards
:
: NM has received honoraria from Chugai, AstraZeneca, Pfizer, Eli Lilly, Eisai, and Takeda; funding from Chugai, AstraZeneca, Kyowa Hakko Kirin, MSD, Novartis, Pfizer, Eli Lilly, Eisai, and Daiichi Sankyo; and is a board member of JBCRG. S. Ohtani has received honoraria from Chugai, Eisai, AstraZeneca, and Pfizer. T. Takano has received honoraria from Daiichi Sankyo, Kyowa Hakko Kirin, and Eisai; and research funding from Chugai, Taiho, Novartis, Takeda, Ono, MSD, Merck Serono, Daiichi Sankyo, Kyowa Hakko Kirin, and Eisai. K. Inoue has received funding from Parexel, Puma Biotechnology, GlaxoSmithKline, Pfizer, Novartis, Chugai, Bayer, Daiichi Sankyo, MSD, and Eli Lilly. HB has received honoraria from Chugai, AstraZeneca, Eisai, Taiho, Novartis, Pfizer, Kyowa Hakko Kirin; and research funding from Taiho and Eisai. YI has received funding from Daiichi Sankyo, Chugai, Novartis, Parexel, EPS, MSD, AstraZeneca, Eli Lilly, Kyowa Hakko Kirin, Covance, Taiho, and A2 Healthcare. TY has received lecture fee from Chugai, Eisai, Novartis, Pfizer, and Taiho. KK has received honoraria from Taiho Pharmaceutical Co, Kyowa Hakko Kirin Co, Astellas Pharma Inc, Eisai Co, and Novartis Pharma K.K. T. Takasuka is an employee and owns stocks of Chugai Pharmaceutical. SM received consulting fees or honoraria from JBCRG and Chugai. S Ohno received consulting fees or honoraria from Chugai, AstraZeneca, Taiho, Pfizer, Novartis, Kyowa Hakko Kirin, and Eisai; and funding from Chugai, Taiho, Daiichi Sankyo, and Eisai. MT received honoraria for lecture from Chugai and Takeda and funding from Chugai. ES, RN, K Ishida, HY, HK, TS, and TRK do not have any conflicts of interest to declare.
: The experiments in this study comply with the current laws of the country in which they were performed.
: Informed consent was obtained from all individual participants included in the study.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.